Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Synimmune
Tübingen, Baden-Württemberg, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
Synimmune developed a clinical-stage, Fc-enhanced monoclonal antibody targeting FLT3 (FLYSYN) for acute myeloid leukemia. The Phase 1 trial in AML patients at high risk of relapse showed the therapy was safe, well tolerated, and demonstrated early signs of efficacy in 31 patients. The company also had preclinical or early-stage assets targeting CD19 and CD133.
- Therapeutic areas
- HematologyOncology
- Modalities
- Monoclonal antibodyAntibody
- Industry
- Biotech
Beyond the preview
Go deeper on Synimmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synimmune.